FDA Reviews Shionogi’s COVID-19 Prevention Pill NDA as the First Oral Therapy
September 2, 2025
Application is based on results from SCORPIO-PEP, the first and only Phase 3 study of an oral antiviral to meet the primary endpoint of preventing